Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

INVO Fertility (IVF) Current Deferred Revenue (2018 - 2025)

INVO Fertility (IVF) has disclosed Current Deferred Revenue for 8 consecutive years, with $720407.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 28.09% to $720407.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $720407.0, a 28.09% increase, with the full-year FY2024 number at $602359.0, up 47.36% from a year prior.
  • Current Deferred Revenue was $720407.0 for Q3 2025 at INVO Fertility, down from $834850.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.4 million in Q1 2021 to a low of $5793.0 in Q1 2022.
  • A 5-year average of $544797.6 and a median of $416745.0 in 2024 define the central range for Current Deferred Revenue.
  • Biggest YoY gain for Current Deferred Revenue was 1931.8% in 2022; the steepest drop was 99.83% in 2022.
  • INVO Fertility's Current Deferred Revenue stood at $5900.0 in 2021, then surged by 1931.8% to $119876.0 in 2022, then soared by 240.99% to $408769.0 in 2023, then soared by 47.36% to $602359.0 in 2024, then increased by 19.6% to $720407.0 in 2025.
  • Per Business Quant, the three most recent readings for IVF's Current Deferred Revenue are $720407.0 (Q3 2025), $834850.0 (Q2 2025), and $725330.0 (Q1 2025).